Retrospective and Prospective Cohort of Patients Entering the Multidisciplinary Management of Post-Covid Syndromes
Recruiting
Observational Study
Post-Covid Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 750 (estimated)
- Sponsor
- Hospices Civils de Lyon · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
SARS-CoV2 pneumonia has been a global public health emergency since 2020. The prevalence of the disease is particularly high with more than 500 million cases worldwide (7.5 million in France) since the emergence of the virus.
A substantial proportion of patients with SARS-Cov2 infection present persistent symptoms long after the acute infection. This is independent of the degree of severity of th…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
All patients who have joined the Epsilon care pathway since its opening in February 2022, i.e.:
* Patients with post-Covid syndrome referred to the Epsilon sector from the city medicine:
* Patient with documented SARS-Cov2 pneumonia
* With persistent and severe symptoms beyond …
Contacts